• Je něco špatně v tomto záznamu ?

Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models

O. Uher, K. Hadrava Vanova, R. Labitt, K. Petrlakova, J. Ye, H. Wang, M. Masarik, M. Jakubek, J. Zenka, Z. Zhuang, K. Pacak

. 2025 ; 612 (-) : 217464. [pub] 20250112

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009686

Neoadjuvant immunotherapy represents a pioneering approach in the preoperative treatment of cancer, providing new strategies for tumor reduction and improved patient outcomes by modulating the immune response. This study investigated neoadjuvant immunotherapy using intratumoral administration of mannan-BAM, Toll-like receptor ligands, and anti-CD40 antibody (MBTA therapy) followed by surgery in murine models of MTT pheochromocytoma, B16-F10 melanoma, and 4T1 and E0771.lmb mammary carcinomas. In the MTT pheochromocytoma model, it was found that neoadjuvant MBTA therapy followed by surgery could prevent the development of distant metastases in 100% of treated animals, compared to a 60% mortality rate in the control group due to metastatic disease after surgery. These outcomes were achieved even in tumors three times larger than those in the control group. In the aggressive 4T1 model, neoadjuvant MBTA therapy resulted in slower tumor progression and a significant prolongation of survival. In the B16-F10 and E0771.lmb models, neoadjuvant MBTA therapy also protected animals from metastases development and tumor recurrence upon rechallenge with tumor cells after surgery. Transcriptomic analysis revealed enhanced effector immune cell infiltration, cytotoxicity, and antigen presentation in retransplanted tumors from MBTA-treated mice, indicating robust immune memory. Notably, the exclusion of the anti-CD40 antibody from the neoadjuvant MBTA therapy (MBT therapy) yielded comparable outcomes in protection against metastases development. These findings advocate for further investigation of intratumoral neoadjuvant MBTA therapy for immunologically "cold" tumors, including those at high risk of metastases or recurrence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009686
003      
CZ-PrNML
005      
20250429134532.0
007      
ta
008      
250415e20250112ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.canlet.2025.217464 $2 doi
035    __
$a (PubMed)39809356
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Uher, Ondrej $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA
245    10
$a Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models / $c O. Uher, K. Hadrava Vanova, R. Labitt, K. Petrlakova, J. Ye, H. Wang, M. Masarik, M. Jakubek, J. Zenka, Z. Zhuang, K. Pacak
520    9_
$a Neoadjuvant immunotherapy represents a pioneering approach in the preoperative treatment of cancer, providing new strategies for tumor reduction and improved patient outcomes by modulating the immune response. This study investigated neoadjuvant immunotherapy using intratumoral administration of mannan-BAM, Toll-like receptor ligands, and anti-CD40 antibody (MBTA therapy) followed by surgery in murine models of MTT pheochromocytoma, B16-F10 melanoma, and 4T1 and E0771.lmb mammary carcinomas. In the MTT pheochromocytoma model, it was found that neoadjuvant MBTA therapy followed by surgery could prevent the development of distant metastases in 100% of treated animals, compared to a 60% mortality rate in the control group due to metastatic disease after surgery. These outcomes were achieved even in tumors three times larger than those in the control group. In the aggressive 4T1 model, neoadjuvant MBTA therapy resulted in slower tumor progression and a significant prolongation of survival. In the B16-F10 and E0771.lmb models, neoadjuvant MBTA therapy also protected animals from metastases development and tumor recurrence upon rechallenge with tumor cells after surgery. Transcriptomic analysis revealed enhanced effector immune cell infiltration, cytotoxicity, and antigen presentation in retransplanted tumors from MBTA-treated mice, indicating robust immune memory. Notably, the exclusion of the anti-CD40 antibody from the neoadjuvant MBTA therapy (MBT therapy) yielded comparable outcomes in protection against metastases development. These findings advocate for further investigation of intratumoral neoadjuvant MBTA therapy for immunologically "cold" tumors, including those at high risk of metastases or recurrence.
650    _2
$a zvířata $7 D000818
650    12
$a neoadjuvantní terapie $x metody $7 D020360
650    _2
$a myši $7 D051379
650    12
$a imunoterapie $x metody $7 D007167
650    _2
$a ženské pohlaví $7 D005260
650    12
$a melanom experimentální $x imunologie $x terapie $x patologie $7 D008546
650    12
$a lokální recidiva nádoru $x prevence a kontrola $7 D009364
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a antigeny CD40 $x imunologie $x antagonisté a inhibitory $7 D019013
650    _2
$a mannany $x farmakologie $7 D008351
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a myši inbrední BALB C $7 D008807
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hadrava Vanova, Katerina $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA
700    1_
$a Labitt, Rachael $u Research Animal Management Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA
700    1_
$a Petrlakova, Katerina $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ye, Juan $u Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
700    1_
$a Wang, Herui $u Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
700    1_
$a Masarik, Michal $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Vestec, Czech Republic
700    1_
$a Jakubek, Milan $u BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Vestec, Czech Republic; Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Zenka, Jan $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic
700    1_
$a Zhuang, Zhengping $u Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
700    1_
$a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA; AKESO, Prague 5, Czech Republic. Electronic address: karel@mail.nih.gov
773    0_
$w MED00001044 $t Cancer letters $x 1872-7980 $g Roč. 612 (20250112), s. 217464
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39809356 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134528 $b ABA008
999    __
$a ok $b bmc $g 2311204 $s 1246767
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 612 $c - $d 217464 $e 20250112 $i 1872-7980 $m Cancer letters $n Cancer Lett $x MED00001044
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace